Genmab — Januar 2017
-
Michael Voss snakker om Darzalex og de nye forsøg i solide tumorer, men intet nyt deri. http://borsen.dk/nyheder/avisen/artikel/11/160193/artikel.html?hl=YToxOntpOjA7czo2OiJHZW5tYWIiO30,
-
Det er i "Investor" tillægget Genmab er omtalt flere steder i dag.
-
Michael Voss, Fundamental Invest, har i øvrigt tæt på 10% i både Genmab og Bavarian i sin fund http://fundamental.gws.fcnws.com/PDF.html?pdf_isin=DK0016272602&pdf_culture=&pdf_filename=DK0016272602_.pdf
-
Ikke dårligt. Han er jo faktisk verdens bedste aktieforvalter på 5 års sigt
-
er det i den fysiske børsen, at det indlæg er??
-
Ja..Investortillægget er også på den digitale side under "Avisen".
-
Gap-luk? Så skal vi i 1214!
-
Teknisk analyse på Genmab på Børsen Play: https://play.borsen.dk/social/587231fb45628ff8171f7da7
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind